Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Enanta received a consensus recommendation of “Moderate Buy” from eight analysts (seven buy, one sell) with an average 12‑month price target of about $20.29.
• In the latest quarter Enanta beat estimates—reporting EPS of ($0.42) vs. ($0.54) expected and revenue of $18.62M vs. $16.14M—but remains unprofitable with negative net margin and ROE, and analysts forecast roughly −4.65 EPS for the fiscal year.
• Shares trade around $13.14 (50‑day SMA $13.43, 200‑day SMA $12.73) with a 12‑month range of $4.09–$17.15, a market cap of about $381M, and about 95% institutional ownership.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight analysts that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $20.2857.

ENTA has been the topic of several recent analyst reports. Rodman & Renshaw began coverage on Enanta Pharmaceuticals in a research note on Thursday, March 26th. They issued a "buy" rating and a $20.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 10th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, January 21st.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Meeder Asset Management Inc. acquired a new stake in shares of Enanta Pharmaceuticals in the 4th quarter valued at about $32,000. Seven Fleet Capital Management LP acquired a new position in Enanta Pharmaceuticals during the 4th quarter worth approximately $36,000. Strs Ohio bought a new position in Enanta Pharmaceuticals in the fourth quarter worth approximately $50,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Enanta Pharmaceuticals by 333.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company's stock valued at $57,000 after acquiring an additional 2,758 shares during the period. Finally, Quarry LP acquired a new stake in Enanta Pharmaceuticals in the third quarter valued at approximately $81,000. Institutional investors and hedge funds own 94.99% of the company's stock.

Enanta Pharmaceuticals Trading Up 1.3%

Shares of ENTA opened at $13.14 on Friday. The firm's fifty day simple moving average is $13.43 and its two-hundred day simple moving average is $12.73. Enanta Pharmaceuticals has a 12 month low of $4.09 and a 12 month high of $17.15. The stock has a market capitalization of $381.32 million, a P/E ratio of -4.11 and a beta of 0.99.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.12. Enanta Pharmaceuticals had a negative return on equity of 78.58% and a negative net margin of 106.80%.The firm had revenue of $18.62 million during the quarter, compared to analyst estimates of $16.14 million. As a group, research analysts predict that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE's direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.